Bruce E. Johnson

Somatic mutations affect key pathways in lung adenocarcinoma (2008)

Ding, Li, Getz, Gad, Wheeler, David A., Mardis, Elaine R., McLellan, Michael D., Cibulskis, Kristian, ...

Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well- classified primary tumours. Here we report the results of a collaborative...

A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer 1 (2008)

Panos Fidias, Jeffrey G. Supko, Renato Martins, Anthony Boral, Robert Carey, Michael Grossbard, ...

Purpose: Our aim was to evaluate the efficacy, toxicity, and pharmacokinetic behavior of single-agent paclitaxel given weekly to elderly patients with lung cancer. Experimental Design: Previously...

Characterizing the cancer genome in lung adenocarcinoma (2007)

Weir, Barbara A., Woo, Michele S., Getz, Gad, Perner, Sven, Ding, Li, Beroukhim, Rameen, ...

Somatic alterations in cellular DNA underlie almost all human cancers(1). The prospect of targeted therapies(2) and the development of high-resolution, genome-wide approaches(3-8) are now spurring...

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations (2005)

Mukohara, Toru, Engelman, Jeffrey A., Hanna, Nasser H., Yeap, Beow Y., Kobayashi, Susumu, Lindeman, Neal, ...

Background: Many patients with non–small-cell lung cancer (NSCLC) who achieve radiographic responses to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors...

A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer (2000)

Chen, T. Timothy, Chute, John P., Feigal, Ellen, Johnson, Bruce E., Simon, Richard

Background: Many more phase II studies have favorable outcomes than the subsequent phase III trials. We used historical data from phase II and phase III studies for patients with extensive-stage...

Second Lung Cancers in Patients After Treatment for an Initial Lung Cancer (1998)

Johnson, Bruce E.

Background: Prospectively and retrospectively identified patient cohorts that were successfully treated for primary lung cancer have been followed to document the rate of development of and the...

Differential Inactivation of CDKN2 and Rb Protein in Non—Small-Cell and Small-Cell Lung Cancer Cell Lines (1995)

Kelley, Michael J., Nakagawa, Kazuhiko, Steinberg, Seth M., Mulshine, James L., Kamb, Alexander, Johnson, Bruce E.

Background: The CDKN2 gene encodes the human cyclin-dependent kinase 4 inhibitor. This inhibitor protein is believed to be a tumor suppressor that plays an essential role in cell cycle regulation....

Obesity and Therapy-Related Toxicity in Patients Treated for Small-Cell Lung Cancer (1995)

Georgiadis, Mark S., Steinberg, Seth M., Hankins, Lynn A., Ihde, Daniel C., Johnson, Bruce E.

Background Obese individuals have altered pharmacokinetics for many medications when compared with the non-obese. For the oncologist treating an obese cancer patient, these changes in drug...

Antibodies Against Autologous Tumor Cell Proteins in Patients With Small-Cell Lung Cancer: Association With Improved Survival (1993)

Winter, Stefan F., Sekido, Yoshitaka, Minna, John D., McIntire, Donald, Johnson, Bruce E., Gazdar, Adi F., ...

Background: The frequency and clinical relevance of human anti-tumor immune responses is not well known, and few target antigens have been identified. Purpose: This study was designed to determine...

Correlation of In Vitro Drug-Sensitivity Testing Results With Response to Chemotherapy and Survival in Extensive-Stage Small Cell Lung Cancer: A Prospective Clinical Trial (1990)

Gazdar, Adi F., Steinberg, Seth M., Russell, Edward K., Linnoila, R. Ilona, Oie, Herbert K., Ghosh, Bimal C., ...

We devised a novel clinical protocol for extensive-stage small cell lung cancer (SCLC), selecting chemotherapy whenever possible on the basis of in vitro drug-sensitivity testing (DST) of individual...

Expression of the Atrial Natriuretic Factor Gene in small Cell Lung Cancer Tumors and Tumor Cell Lines (1990)

Bliss, David P., Battey, James F., Linnoila, R. Ilona, Birrer, Michael J., Gazdar, Adi F., Johnson, Bruce E.

Hyponatremia in patients with small cell lung cencer can be caused by tumor production of arginine vasopression (AVP) and result in the sundrome of inappropriate antidiuretic hormone. In evaluating...

MDR1 Gene Expression in Lung Cancer (1989)

Lai, Shinn-Liang, Goldstein, Lori J., Gottesman, Michael M., Pastan, Ira, Tsai, Chun-Ming, Johnson, Bruce E., ...

The MDR1 gene (also known as PGY1) is frequently overexpressed in multidrug-resistant cell lines. We investigated the role of MDR1 gene expression in lung cancer by performing RNA slot blot analysis...

Retention of Chromosome 3 in Extrapulmonary Small Cell Cancer Shown by Molecular and Cytogenetic Studies (1989)

Johnson, Bruce E., Whang-Peng, Jacqueline, Naylor, Susan L., Zbar, Berton, Brauch, Hiltrud, Lee, Elaine, ...

In small cell lung carcinoma, one of the short arms of chromosome 3 is typically lost. To investigate chromosome 3 in extrapulmonary small cell carcinoma, we used DNA probes that detect...

Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes

Ivanov, Sergey V., Kuzmin, Igor, Wei, Ming-Hui, Pack, Svetlana, Geil, Laura, Johnson, Bruce E., ...

To discover genes involved in von Hippel-Lindau (VHL)-mediated carcinogenesis, we used renal cell carcinoma cell lines stably transfected with wild-type VHL-expressing transgenes. Large-scale RNA...

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

Bhattacharjee, Arindam, Richards, William G., Staunton, Jane, Li, Cheng, Monti, Stefano, Vasa, Priya, ...

We have generated a molecular taxonomy of lung carcinoma, the leading cause of cancer death in the United States and worldwide. Using oligonucleotide microarrays, we analyzed mRNA expression levels...

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, Jeffrey A., Jänne, Pasi A., Mermel, Craig, Pearlberg, Joseph, Mukohara, Toru, Fleet, Christina, ...

Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in intracellular...

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, Jeffrey A., Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borrás, Ana M., Gale, Christopher-Michael, ...

EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with acquired resistance but...

Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes

Ivanov, Sergey V., Kuzmin, Igor, Wei, Ming-Hui, Pack, Svetlana, Geil, Laura, Johnson, Bruce E., ...

To discover genes involved in von Hippel-Lindau (VHL)-mediated carcinogenesis, we used renal cell carcinoma cell lines stably transfected with wild-type VHL-expressing transgenes. Large-scale RNA...

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

Bhattacharjee, Arindam, Richards, William G., Staunton, Jane, Li, Cheng, Monti, Stefano, Vasa, Priya, ...

We have generated a molecular taxonomy of lung carcinoma, the leading cause of cancer death in the United States and worldwide. Using oligonucleotide microarrays, we analyzed mRNA expression levels...

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, Jeffrey A., Jänne, Pasi A., Mermel, Craig, Pearlberg, Joseph, Mukohara, Toru, Fleet, Christina, ...

Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in intracellular...

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Engelman, Jeffrey A., Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borrás, Ana M., Gale, Christopher-Michael, ...

EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with acquired resistance but...